Literature DB >> 31977296

Genomic and Epigenomic Alterations in Chronic Lymphocytic Leukemia.

Ferran Nadeu1,2, Ander Diaz-Navarro2,3, Julio Delgado1,2,4, Xose S Puente2,3, Elías Campo1,2,5.   

Abstract

Chronic lymphocytic leukemia is a common disease in Western countries and has heterogeneous clinical behavior. The relevance of the genetic basis of the disease has come to the forefront recently, with genome-wide studies that have provided a comprehensive view of structural variants, somatic mutations, and different layers of epigenetic changes. The mutational landscape is characterized by relatively common copy number alterations, a few mutated genes occurring in 10-15% of cases, and a large number of genes mutated in a small number of cases. The epigenomic profile has revealed a marked reprogramming of regulatory regions in tumor cells compared with normal B cells. All of these alterations are differentially distributed in clinical and biological subsets of the disease, indicating that they may underlie the heterogeneous evolution of the disease. These global studies are revealing the molecular complexity of chronic lymphocytic leukemia and provide new perspectives that have helped to understand its pathogenic mechanisms and improve the clinical management of patients.

Entities:  

Keywords:  chronic lymphocytic leukemia; cytogenetics; epigenomics; genomics; next-generation sequencing

Mesh:

Year:  2020        PMID: 31977296     DOI: 10.1146/annurev-pathmechdis-012419-032810

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  7 in total

1.  Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients.

Authors:  Tycho Baumann; Riccardo Moia; Gianluca Gaidano; Julio Delgado; Adalgisa Condoluci; Neus Villamor; Anil Babu Payedimarri; Dolors Costa; Andrea Patriarca; Carlos Jiménez-Vicente; Davide Rossi; Emili Montserrat
Journal:  Leukemia       Date:  2021-02-04       Impact factor: 11.528

2.  Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.

Authors:  Julio Delgado; Ferran Nadeu; Dolors Colomer; Elias Campo
Journal:  Haematologica       Date:  2020-07-02       Impact factor: 9.941

3.  IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.

Authors:  Ferran Nadeu; Romina Royo; Guillem Clot; Martí Duran-Ferrer; Alba Navarro; Silvia Martín; Junyan Lu; Thorsten Zenz; Tycho Baumann; Pedro Jares; Xose S Puente; José I Martín-Subero; Julio Delgado; Elías Campo
Journal:  Blood       Date:  2021-05-27       Impact factor: 22.113

Review 4.  Research progress on epigenetics of small B-cell lymphoma.

Authors:  Xueqin Ruan; Rong Zhang; Hongkai Zhu; Can Ye; Zhihua Wang; En Dong; Ruijuan Li; Zhao Cheng; Hongling Peng
Journal:  Clin Transl Oncol       Date:  2022-03-25       Impact factor: 3.340

5.  PanCancer analysis of somatic mutations in repetitive regions reveals recurrent mutations in snRNA U2.

Authors:  Pablo Bousquets-Muñoz; Ander Díaz-Navarro; Ferran Nadeu; Ana Sánchez-Pitiot; Sara López-Tamargo; Shimin Shuai; Milagros Balbín; Jose M C Tubio; Sílvia Beà; Jose I Martin-Subero; Ana Gutiérrez-Fernández; Lincoln D Stein; Elías Campo; Xose S Puente
Journal:  NPJ Genom Med       Date:  2022-03-14       Impact factor: 6.083

Review 6.  Long Non-Coding RNA Neighbor of BRCA1 Gene 2: A Crucial Regulator in Cancer Biology.

Authors:  Ting Wang; Zhaosheng Li; Liujia Yan; Feng Yan; Han Shen; Xinyu Tian
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

Review 7.  Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.

Authors:  Julio Delgado; Ferran Nadeu; Dolors Colomer; Elias Campo
Journal:  Haematologica       Date:  2020-09-01       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.